logo
  • About Us
    • Who We Are
    • Leadership Team
    • Our Story
    • Patent
    • Contact Us
  • Science & Pipeline
    • The Science of RNAi
    • Pipeline
      • Oncology
      • Fibrosis
      • Medical Aesthetic
      • Antiviral
      • GaINAc-RNAi triggers
    • Research & Development
    • Clinical Studies
    • Clinical Manufacturing
  • Investor Relations
    • Analyst Coverage
      • Stock Chart
      • Analyst Coverage
    • Information Disclosure
      • Announcements & Circulars
      • Financial Reports
      • Listing Documents
      • ESG Reports
    • Events & Presentations
    • Corporate Governance
    • Investor Enquiries
  • Partnership
    • Business Development
    • Our Partners
  • News
    • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Sirnaomics In The News
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • news
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Sirnaomics Ltd. Listed on Main Board of HKEX
      • Sirnaomics Receives Safe to Proceed Letter for U.S. FDA Investigational New Drug Application for Systemic RNAi Therapeutic STP707 in Primary Sclerosing Cholangitis (PSC)
      • Sirnaomics Announces Interim Data from Phase II Clinical Trial of STP705 for Treatment of Cutaneous Basal Cell Carcinoma
      • Sirnaomics to Present Latest Developments on its GalNAc-Based Liver-Targeting Platforms and Product Pipeline at the 2022 Oligonucleotide & Precision Therapeutics Congress
      • RNAimmune Secures $27 Million Series A Round of Financing for Development of mRNA Therapeutics and Vaccines
      • Sirnaomics Doses First Subject in Phase I Clinical Trial of STP707 for the Treatment of Liver Fibrosis in Primary Sclerosing Cholangitis
      • Sirnaomics Launches Phase I Clinical Trial of RNAi Therapeutic STP707 Delivered Systemically for the Treatment of Solid Tumors
      • Sirnaomics to Present Latest Developments on its GalNAc-Based Liver-Targeting Platforms and GalAhead™ Programs at the TIDES USA 2022  
      • Sirnaomics will present clinical study results and development strategy for Cancer RNA Therapeutics at the 2022 Pre-ASCO China Summit
      • Sirnaomics Launches Phase I Clinical Trial of RNAi Therapeutic STP705 in Adults Undergoing Abdominoplasty for Medical Cosmetology Treatment
      • Sirnaomics Announces Publication of STP705 Clinical Study Results for Treatment of isSCC in the Peer-Reviewed Journal of Drugs in Dermatology
      • Sirnaomics to Present the Latest Developments of Dual-Targeted RNAi Therapeutics based on its Proprietary GalAhead™ Program at the 4th Annual RNA Therapeutic: From Concept to Clinic Symposium
    • Sirnaomics in the News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • After a $50M IPO, Sirnaomics aims to market the first RNAi drug for oncology
      • Shortly after its latest mega-round, Sirnaomics CEO Patrick Lu says it's time to go public
    • Media Outreach
  • Careers
    • Working at Sirnaomics
    • Join Us
EN 简 繁
img img img
  • About Us
    • Who We Are
    • Leadership Team
    • Our Story
    • Patent
    • Contact Us
  • Science & Pipeline
    • The Science of RNAi
    • Pipeline
      • Oncology
      • Fibrosis
      • Medical Aesthetic
      • Antiviral
      • GaINAc-RNAi triggers
    • Research & Development
    • Clinical Studies
    • Clinical Manufacturing
  • Investor Relations
    • Analyst Coverage
      • Stock Chart
      • Analyst Coverage
    • Information Disclosure
      • Announcements & Circulars
      • Financial Reports
      • Listing Documents
      • ESG Reports
    • Events & Presentations
    • Corporate Governance
    • Investor Enquiries
  • Partnership
    • Business Development
    • Our Partners
  • News
    • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Sirnaomics In The News
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • news
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Sirnaomics Ltd. Listed on Main Board of HKEX
      • Sirnaomics Receives Safe to Proceed Letter for U.S. FDA Investigational New Drug Application for Systemic RNAi Therapeutic STP707 in Primary Sclerosing Cholangitis (PSC)
      • Sirnaomics Announces Interim Data from Phase II Clinical Trial of STP705 for Treatment of Cutaneous Basal Cell Carcinoma
      • Sirnaomics to Present Latest Developments on its GalNAc-Based Liver-Targeting Platforms and Product Pipeline at the 2022 Oligonucleotide & Precision Therapeutics Congress
      • RNAimmune Secures $27 Million Series A Round of Financing for Development of mRNA Therapeutics and Vaccines
      • Sirnaomics Doses First Subject in Phase I Clinical Trial of STP707 for the Treatment of Liver Fibrosis in Primary Sclerosing Cholangitis
      • Sirnaomics Launches Phase I Clinical Trial of RNAi Therapeutic STP707 Delivered Systemically for the Treatment of Solid Tumors
      • Sirnaomics to Present Latest Developments on its GalNAc-Based Liver-Targeting Platforms and GalAhead™ Programs at the TIDES USA 2022  
      • Sirnaomics will present clinical study results and development strategy for Cancer RNA Therapeutics at the 2022 Pre-ASCO China Summit
      • Sirnaomics Launches Phase I Clinical Trial of RNAi Therapeutic STP705 in Adults Undergoing Abdominoplasty for Medical Cosmetology Treatment
      • Sirnaomics Announces Publication of STP705 Clinical Study Results for Treatment of isSCC in the Peer-Reviewed Journal of Drugs in Dermatology
      • Sirnaomics to Present the Latest Developments of Dual-Targeted RNAi Therapeutics based on its Proprietary GalAhead™ Program at the 4th Annual RNA Therapeutic: From Concept to Clinic Symposium
    • Sirnaomics in the News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • After a $50M IPO, Sirnaomics aims to market the first RNAi drug for oncology
      • Shortly after its latest mega-round, Sirnaomics CEO Patrick Lu says it's time to go public
    • Media Outreach
  • Careers
    • Working at Sirnaomics
    • Join Us
QR
logo
Sirnaomics Ltd.

401 Professional Dr, STE 280 Gaithersburg, MD 20879, USA

© 2007-2022 by Sirnaomics
  • About Us
    • Who We Are
    • Leadership Team
    • Our Story
    • Patent
    • Contact Us
  • Science & Pipeline
    • The Science of RNAi
    • Pipeline
      • Oncology
      • Fibrosis
      • Medical Aesthetic
      • Antiviral
      • GaINAc-RNAi triggers
    • Research & Development
    • Clinical Studies
    • Clinical Manufacturing
  • Investor Relations
    • Analyst Coverage
      • Stock Chart
      • Analyst Coverage
    • Information Disclosure
      • Announcements & Circulars
      • Financial Reports
      • Listing Documents
      • ESG Reports
    • Events & Presentations
    • Corporate Governance
    • Investor Enquiries
  • Partnership
    • Business Development
    • Our Partners
  • News
    • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Sirnaomics In The News
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • news
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Sirnaomics Ltd. Listed on Main Board of HKEX
      • Sirnaomics Receives Safe to Proceed Letter for U.S. FDA Investigational New Drug Application for Systemic RNAi Therapeutic STP707 in Primary Sclerosing Cholangitis (PSC)
      • Sirnaomics Announces Interim Data from Phase II Clinical Trial of STP705 for Treatment of Cutaneous Basal Cell Carcinoma
      • Sirnaomics to Present Latest Developments on its GalNAc-Based Liver-Targeting Platforms and Product Pipeline at the 2022 Oligonucleotide & Precision Therapeutics Congress
      • RNAimmune Secures $27 Million Series A Round of Financing for Development of mRNA Therapeutics and Vaccines
      • Sirnaomics Doses First Subject in Phase I Clinical Trial of STP707 for the Treatment of Liver Fibrosis in Primary Sclerosing Cholangitis
      • Sirnaomics Launches Phase I Clinical Trial of RNAi Therapeutic STP707 Delivered Systemically for the Treatment of Solid Tumors
      • Sirnaomics to Present Latest Developments on its GalNAc-Based Liver-Targeting Platforms and GalAhead™ Programs at the TIDES USA 2022  
      • Sirnaomics will present clinical study results and development strategy for Cancer RNA Therapeutics at the 2022 Pre-ASCO China Summit
      • Sirnaomics Launches Phase I Clinical Trial of RNAi Therapeutic STP705 in Adults Undergoing Abdominoplasty for Medical Cosmetology Treatment
      • Sirnaomics Announces Publication of STP705 Clinical Study Results for Treatment of isSCC in the Peer-Reviewed Journal of Drugs in Dermatology
      • Sirnaomics to Present the Latest Developments of Dual-Targeted RNAi Therapeutics based on its Proprietary GalAhead™ Program at the 4th Annual RNA Therapeutic: From Concept to Clinic Symposium
    • Sirnaomics in the News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • After a $50M IPO, Sirnaomics aims to market the first RNAi drug for oncology
      • Shortly after its latest mega-round, Sirnaomics CEO Patrick Lu says it's time to go public
    • Media Outreach
  • Careers
    • Working at Sirnaomics
    • Join Us